Anal cancer incidence and mortality have been increasing over the past decade. Although the incidence in the general population remains low, it is much higher in certain subgroups, including those living with human immunodeficiency virus and men who have sex with men. Approximately 90% of anal squamous cell cancers are caused by infection with carcinogenic human papillomavirus (HPV). Given the common etiology between anal and cervical carcinogenesis, screening for anal cancer has been proposed in certain high-risk populations using strategies adapted from cervical cancer prevention.
with incidence rates ranging from 77 to 137 per 100,000, 2,3 exceeding incidence rates of cervical cancer in some countries without screening. 4 The excess burden of anal cancer in these populations is attributed in part to the higher prevalence of HPV. HPV vaccination has demonstrated good efficacy for primary anal cancer prevention 5, 6 ; however, the vaccine is only recommended for men up to age 27 years, and uptake has been limited. 7 Given the high incidence of anal cancer in certain high-risk groups, such as HIV-positive MSM, there has been interest in developing screening and surveillance strategies that target these populations. The common etiology between anal and cervical carcinogenesis has prompted evaluations of cervical cancer screening and prevention approaches in anal cancer. However, there are important differences in the populations at risk, disease natural history, and clinical procedures and outcomes that need to be considered when evaluating strategies that have been introduced for cervical cancer prevention.
Natural History of Cervical Cancers Compared With Anal Cancers
A functional progression model that has been established for cervical cancer includes 3 major steps (Fig. 1A ) [8] [9] [10] [11] [12] [13] : HPV infection in the cervical transformation zone, followed by persistence and progression to precancer, and invasion to cancer. 8, 14 Almost all cervical cancers are caused by carcinogenic HPV infections. These infections are common in sexually active women, but most newly acquired HPV infections become undetectable after a few months. A small subset of infections persists and may progress to cervical precancers (cervical intraepithelial neoplasia grade 3 [CIN3]). Without intervention, approximately one-third of cervical precancers ultimately will invade after 20 to 30 years. 15 Approximately 90% of anal squamous cell carcinomas (SCCs) are attributed to infection with high-risk HPV (HR-HPV). 16 The anus, like the cervix, has a transformation zone where squamous epithelium of the anus transitions to columnar epithelium of the rectum, which is susceptible to HPV infection and subsequent transformation. 17 Anal cancer develops through characteristic epithelial precursors like cervical cancer, suggesting that the cervical cancer progression model similarly may apply to anal cancer. HR-HPV infection alone is not sufficient for anal carcinogenesis, but determinants of HPV persistence and progression to precancer are not well understood. High-grade anal intraepithelial neoplasia (AIN) Cervical cancer arises through 3 major steps: HPV infection, followed by persistence and progression to precancer, and invasion to cancer. The peak prevalence of HPV infection follows the initiation of sexual activity. The secondary peak of precancer occurs several years later, depending on screening, whereas the peak or plateau of cancer occurs about 30 years after the initial HPV infection peak. Anal cancer develops through characteristic epithelial precursors like cervical cancer, suggesting that (B) the cervical cancer progression model may similarly apply to anal cancer. In contrast to cervical HPV infection, (C) anal HPV prevalence in all men who have sex with men (MSM) and (D) and in human immunodeficiency (HIV)-positive MSM is elevated across most age groups. Similarly, anal precancers do not show a characteristic age peak. Green lines indicate HPV prevalence, and blue lines indicate precancer prevalence. The age-prevalence curve for cervix was adapted from Schiffman and Wentzensen, 8 and the age-prevalence curves for the anal region are summarized from several sources.
(AIN2/AIN3) is considered the precursor to invasive anal SCC. Very few studies have evaluated the progression rate of AIN2/AIN3 to anal cancer, but it has been suggested that progression from anal precancer to cancer may be less common compared with cervical precancers. 18 However, there is a lot of uncertainty around the invasion estimates for both cancer sites.
19,20

Prevalence of Cervical and Anal HPV Infection and Precancer in the Population
The individual steps of the cervical cancer progression model have very characteristic age distributions in the population (Fig. 1B) . HPV infections peak around age 20 years, shortly after the initiation of sexual activity. Cervical precancers peak approximately 10 years later. The highest prevalence of invasive cancers in the population occurs about 30 years after the initial infection peak, at approximately ages 35 to 55 years in unscreened populations, indicating that the development of cancer from an initial infection typically takes decades. 8, 14 In stark contrast, anal HPV prevalence in MSM (Fig. 1C ) and in HIV-positive MSM (Fig. 1D ) is high across most age groups. 21, 22 Similarly, anal precancers do not have a characteristic age peak (Fig. 1C,D) , and diagnosis of anal cancer peaks from approximately ages 45 to 64 years. 23 Among those with normal anal cytology, HPV prevalence is approximately 42% and 59% in HIV-negative and HIV-positive women, respectively, and 57% and 76% in HIV-negative and HIV-positive men, respectively. 24 In contrast, in HIVnegative men who have sex with women, HPV prevalence is much lower (6%). The prevalence of HPV infection increases with worsening cytology diagnosis, reaching >90% in high-grade squamous intraepithelial lesions (HSIL) and nearly 100% in anal cancer among HIVpositive women and men, respectively. 24 These different patterns of cervical and anal HPV natural history may reflect both biologic (eg, less effective immune control, particularly among HIV-positive MSM) and behavioral factors (eg, high levels of acquisition in older age groups, less screening and removal of earlier precancers).
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HPV Genotype Distribution in Cervical and Anal Disease
The risk of cervical cancer varies strongly across different HPV genotypes. Most are caused by HPV type 16 (HPV16), followed by HPV18, which together account for approximately 75% of cervical cancers. 26 The next 5 carcinogenic types (which are included in the nonavalent vaccine) 27 account for an additional 15%, whereas the remaining types cause only very small proportions of cervical cancers (Fig. 2) . 24, 26, [28] [29] [30] [31] The distribution of HPV genotypes varies strongly by cervical disease stage; the proportion of HPV16 and HPV18 increases substantially with higher grade of disease. 28 Recently, a large systematic review and meta-analysis reported type-specific HPV prevalence across different anal diagnoses by sex and HIV status.
24 HPV16-specific prevalence increased with the severity of anal cytology diagnosis in all subgroups, with a large proportion of cancers (approximately 85%) caused by HPV16 (Fig. 2 ). In contrast, the prevalence of HPV18 and of HPV31, HPV33, HPV45, HPV52, and HPV58 increased from normal to HSIL cytology but decreased in anal cancers in all subgroups. Approximately 85% of HIV-negative anal cancers (Fig. 2 ).
Cervical and Anal Cancer Screening Approaches
Cervical cancer screening is highly efficacious because it detects cervical precancers that can be treated to prevent invasive cancers. At the population level, this is accomplished by identifying a small subset of all screened women who are at increased risk of cervical cancer and need additional workup and possibly treatment. 36 Cervical cytology-based screening has led to dramatic decreases of cervical cancer incidence and mortality over the past decades in many developed countries, and it remains the most widely used screening approach. 37 Recently, HPV testing has been introduced in several countries in addition to, or replacing, cervical cytology as a primary screening test. 37 HPV testing provides great reassurance against developing cervical precancer and cancer in women who test negative, allowing extended screening intervals. 38 HPV-positive women are at increased risk of cervical precancer; however, most infections are transient and do not require further evaluation. Because it is not feasible to refer all HPV-positive women to colposcopy, additional tests (triage tests) are used to identify women at the highest risk of cervical precancer. 36 Currently, there are no randomized clinical trials documenting the effectiveness of an anal screening program to reduce anal cancer incidence, morbidity, or mortality. 39 Previous observational studies have evaluated anal cytology and HPV testing for the detection of anal precancers. HPV testing is recommended for cervical cancer screening among women aged 25 years when HPV prevalence begins to decrease and precancer prevalence increases, making HPV screening efficient to reassure the vast majority of women of a low risk of precancer and cancer. 40 In contrast, HPV prevalence is much higher among HIV-positive MSM, and it does not decrease at older ages, resulting in high test positivity and low specificity. 41 Consequently, far fewer patients can be reassured of a low risk of anal precancer and cancer. We do not know at what HPV prevalence primary HPV testing would be efficient, but the benefit is greatly reduced when most men test positive. It is also not clear how long a negative anal HPV test provides reassurance against anal precancer and cancer. The management of women who test positive in cervical cancer screening relies on colposcopy as the diagnostic gold standard. It has been demonstrated that colposcopy is subjective and that detection of disease strongly depends on how many biopsies are taken. 42 Recently, colposcopy guidelines were established to improve reproducibility and accuracy of colposcopy and biopsy in the United States. 43, 44 Similar to cervical colposcopy, high-resolution anoscopy (HRA) involves visualization of the anal canal and perianus using a colposcope with acetic acid and Lugol iodine to identify anal lesions. 45 Anatomic differences between the anus and the cervix, including a larger surface area and anal mucosal folds that can hide lesions, make HRA more challenging than colposcopy. 46 A higher prevalence of coexisting pathology (eg, condyloma, hemorrhoids, treatment-related scar tissue) also may obscure visualization during HRA. Attempts have been made to standardize HRA by the International Anal Neoplasia Society, 47 but training and techniques vary across different providers from diverse specialties, including infectious disease, HIV and sexual health, colorectal surgery, gynecology, family medicine, and dermatology.
Treatment of Cervical and Anal Precancers
Any public health or clinical intervention like population screening or surveillance of individuals at high risk of disease needs to weigh the benefits of the intervention against the harms. 19 The benefit of cervical cancer screening comes at the cost of treating many cancer precursors that would not progress to invasive cancer. However, because the treatment (excision of the cervical transformation zone) is relatively benign, overtreatment is widely accepted. Obstetric complications are the most important adverse events, but they depend on the depth of excision, and the risk can be safely reduced in most women by performing less deep excisions. 48, 49 An important difference compared with the cervix is that excisions in the anal canal are associated with more Review Article adverse outcomes, which can have long-term complications and affect anal sphincter functions. [50] [51] [52] The decision to treat AIN2/AIN3 and the type of treatment depends on factors such as the size and location of the lesion. Unlike cervical precancer, smaller lesions tend to be treated more often than larger lesions owing to the ease of treating these lesions with topical therapy or excision. In contrast, surgical resection is usually required for larger lesions and can involve substantial morbidity, including pain, anal stenosis, and incontinence along with a high likelihood of recurrence. 53 Patients who have larger lesions are usually closely monitored every 4 to 6 months with repeat HRA to identify signs of progression to early stage anal cancer. Treatment of intra-anal lesions is more difficult than treatment of lesions located on the perianal surface; therefore, lesions located within the anal canal have a higher threshold for treatment, particularly if they are large, and circumferential intra-anal lesions generally are not treated. 43 These anatomic characteristics can vary by HIV status; large lesions tend to be more common in HIV-positive patients and have a higher rate of recurrence compared with those in HIV-negative patients.
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SYSTEMATIC REVIEW OF CYTOLOGY, HPV TESTING, AND OTHER BIOMARKERS FOR THE DETECTION OF ANAL PRECANCER
The availability of various screening and triage markers for cervical precancers has prompted evaluation of these assays for the detection of anal precancer and cancer in various populations. In the sections below, we describe systematic reviews and meta-analyses of anal cytology, anal HPV testing, p16 or p16/Ki-67 dual staining, and HPV E6/E7 messenger RNA (mRNA) testing for the detection of anal precancers and cancers. The objectives of this systematic review and meta-analysis were to assess the diagnostic accuracy (sensitivity and specificity) of the performance of these biomarkers for anal cancer screening and to determine whether these estimates vary by HIV status.
Methods
We conducted this systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Supporting Fig. 1 ). We included original studies with primary data reporting the performance of screening tests and biomarkers for the detection of anal precancers and cancer.
Our search was limited to English-language, peer-reviewed studies published before February, 2018. We searched the MEDLINE database through PubMed and EMBASE using search the terms listed in the Supporting Methods. Titles and abstracts of identified articles were independently screened for inclusion, and full-text versions of eligible articles were reviewed by M.A.C. and N.W. to determine eligibility. We reviewed the reference lists of articles identified in the primary search for additional relevant studies.
Only studies that evaluated anal precancer/cancer as the main outcome(s) were included. In addition, we excluded studies that did not assess screening performance and those with significant verification bias, in which the receipt or interpretation of the diagnostic test (eg, HRA and/or biopsy) depended on results from a prior clinical test (eg, anal cytology). In the case of sequential or multiple publications in which there was a possibility of overlapping data, only data from the most recent publication were included. Although we did not restrict our search to specific populations, most included studies were conducted among MSM and HIV-positive MSM and thus we were not powered to analyze performance estimates among women.
To estimate diagnostic accuracy for anal precancers and cancers, we extracted information on the number of true-positive, false-negative, false-positive, and truenegative findings according to each test. Calculations of summary estimates required data from a minimum of 4 studies and were carried out using a random effects bivariate normal model for the sensitivity and specificity between studies, fit with the Stata metandi and gllam packages (Stata Corporation, College Station, TX). [56] [57] [58] If the study reported separate performance estimates for more than 1 population (eg, HIV-positive MSM and HIV-negative MSM), then we estimated sensitivity and specificity values for each reported population combined in the overall analysis and then separately in analyses stratified by HIV status. Sensitivity and specificity estimates for each study were plotted in a summary receiver operator characteristic (ROC) plot, in which each point on the curve represents a different study, weighted according to sample size.
RESULTS
Performance of Anal Cytology for the Detection of Anal Precancer
Anal cytology was first studied for the detection of anal dysplasia in the 1990s, and anal cytology was first included In total, 14 studies reported on the performance of cytology in detecting anal precancers and cancers, including 881 findings of AIN2 or higher and 3706 findings of AIN2 or lower. 41, [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] The distribution of abnormal cytology results in all 14 studies was 12% ASC-US, 18% LSIL, and 5% HSIL, with prevalence varying significantly by HIV status (Supporting Fig. 2 ). Among 9 studies with available data, the pooled proportion of inadequate cytology results was 3% (95% confidence interval [CI], 2%-5%) (Supporting Fig. 3) . Overall, the pooled sensitivity and specificity of ASC-US-positive cytology for the detection of AIN2 or higher was 77.3% (95% CI, 64.9%-86.3%) and 55.5% (95% CI, 45.5%-65.2%), respectively (Fig. 3) 
Performance of HPV Testing for the Detection of Anal Precancers
Several HPV assays have been evaluated in anal samples from individuals at increased risk of anal cancer. These include signal-amplification (hybridization-based) and target-amplification (polymerase chain reaction-based) Table 1 ). In each plot, the summary value for sensitivity and specificity (red square) is plotted with a 95% confidence region (dashed orange line). Individual studies are shown as hollow circles, with their size determined by the number of participants. The 95% prediction region (green dashed line) represents potential values of sensitivity and specificity that might be observed in a future study by describing the full extent of the uncertainty of the summary points, reflecting the between-study heterogeneity.
assays. 74 Some of these assays have received regulatory approval for use in cervical cancer screening, but there are currently no US Food and Drug Administration-approved tests for anal cancer screening or surveillance. Large studies evaluating HPV DNA assays for cervical cancer screening have demonstrated that the performance of these tests is very similar, [75] [76] [77] [78] [79] [80] allowing the pooling of data across these tests. In total, 9 studies reported on the performance of any HR-HPV test for detecting anal precancers and cancers, including 671 findings of AIN2 or greater and 2154 findings of AIN2 or lower. 41 (Fig. 4) . Among the 8 studies that were restricted to HIVpositive MSM, the pooled sensitivity and specificity was 95.4% (95% CI, 84.6%-98.7%) and 23.8% (95% CI, 16.3%-33.4%), respectively. We lacked a sufficient number of studies to evaluate the performance of HR-HPV testing in other populations. Genotyping for HPV16/HPV18 has the potential to improve the specificity of HPV testing for anal precancer detection. In total, 5 studies reported on the performance of HPV16/HPV18 genotyping for the detection of anal precancers and cancers, including 510 findings of AIN2 or greater and 1562 findings of AIN2 or less. 67, 71, 72, 82, 83 Overall, the pooled sensitivity and specificity of HPV16/ HPV18 for detecting AIN2 or greater was 39.9% (95% CI, 22.4%-60.5%) and 74.3% (95% CI, 67.3%-80.1%), respectively. Among the 4 studies that were restricted to HIV-positive MSM, the pooled sensitivity and specificity was 41.3% (95% CI, 22.2%-63.3%) and 68.5% (95% CI, 63.5%-73.0%), respectively. We lacked a sufficient number of studies to evaluate the performance of HPV16/ HPV18 genotyping in other populations.
Other Biomarkers
Several promising biomarkers are currently being evaluated for cervical cancer screening and triage that may have applications in screening and/or surveillance for anal cancer. Of these, only HPV E6/E7 mRNA testing and immunostaining for p16 or p16/Ki-67 dual staining had a sufficient number of studies to be included in our review.
HPV E6/E7 mRNA
Four studies evaluated the performance of E6/E7 mRNA for the detection of anal precancer and cancer, including a mix of HIV-positive and HIV-negative MSM (Supporting Table 1) . 67, 72, 83, 84 The pooled sensitivity and specificity of Table 1 ). In each plot, the summary value for sensitivity and specificity (red square) is plotted with a 95% confidence region (dashed orange line). Individual studies are shown as hollow circles, with their size determined by the number of participants. The 95% prediction region (green dashed line) represents potential values of sensitivity and specificity that might be observed in a future study by describing the full extent of the uncertainty of the summary points, reflecting the between-study heterogeneity.
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Cancer Cytopathology E6/E7 mRNA was 74.3% (95% CI, 68.3%-79.6%) and 65.5% (95% CI, 58.5%-71.9%), respectively (Fig. 5) . Performance estimates were similar across all studies.
p16 or p16/Ki-67 Immunostaining
Four studies evaluated the performance of p16 staining (n 5 2) or p16/Ki-67 dual staining (n 5 2) for the detection of anal precancer and cancer, including a mix of HIVpositive and HIV-negative MSM (Supporting Table  1) . 67, 72, 83, 85 The pooled sensitivity and specificity of p16/ p16-Ki-67 was 56.6% (95% CI, 27.9%-81.5%) and 62.3% (95% CI, 47.8%-74.9%), respectively, with substantial heterogeneity observed between studies (Fig. 5 ). There were only limited data to assess differences between p16 and p16/Ki-67 dual staining, but it appeared that the p16/Ki-67 dual stain was more accurate than p16 alone for the detection of anal precancer and cancer.
Methylation DNA methylation testing of both host and viral genes has been strongly associated with cervical precancer and cancer and is a promising method for triage of HPV-positive women. [86] [87] [88] [89] Similar findings have been reported for anal precancers and cancers 90 ; however, there have been no studies assessing the clinical performance of methylation for anal cancer screening.
APPLICATION OF BIOMARKERS FOR SCREENING, EARLY DETECTION, AND MANAGEMENT OF ANAL PRECANCERS
The detection of anal precancers may be possible with similar tools that have been established for cervical cancer screening. We systematically evaluated the performance of anal cytology, HPV testing, and biomarkers for the detection of AIN2/AIN3 and cancer. In Table 1 , we put these performance estimates into the context of anal cancer screening among HIV-positive MSM. Our systematic review and meta-analysis demonstrates that the performance of anal cytology differs from that of cervical cytology in a screening population with regard to both sensitivity and specificity. This is because of the greater burden of HPV infection and higher degree of disease severity, particularly among HIV-positive MSM. Performance characteristics of a diagnostic test (ie, cytology) are often thought to be portable between populations with different disease prevalence. However, the combination of a subjective diagnostic test (cytology) with an imperfect reference standard Figure 5 . The clinical performance of biomarkers (anal intraepithelial neoplasia grade 2 or greater outcomes) is illustrated. These are meta-analysis plots of the diagnostic accuracy of (Left) human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) and (Right) p16 or p16/Ki-67 staining. One study was split by human immunodeficiency virus status (see Supporting Table 1 ). In each plot, the summary value for sensitivity and specificity (red square) is plotted with a 95% confidence region (dashed orange line). Individual studies are shown as hollow circles, with their size determined by the number of participants. The 95% prediction region (green dashed line) represents potential values of sensitivity and specificity that might be observed in a future study by describing the full extent of the uncertainty of the summary points, reflecting the between-study heterogeneity. Studies that used p16/Ki-67 are marked with a red asterisk.
(HRA) can affect performance estimates between populations. 91 A higher disease prevalence may improve the sensitivity of anal cytology for detecting disease but can reduce specificity, similar to the cytology performance observed in the triage of HPV-positive women (Fig. 6) . The performance of cytology in other high-risk populations, such as HIV-negative MSM, is highly variable. To inform clinical practice, more studies in this population are needed; and, when possible, the results should be reported within strata of HIV-positive and HIV-negative MSM. Given the high prevalence of HPV in HIV-positive MSM, the role of HPV testing in primary screening for anal cancer may be limited, because too many men would test positive and require additional workup. Indeed, our analysis of the performance of HPV testing indicated high sensitivity but low specificity for HPV testing in studies overall, and especially in those restricted to HIV-positive MSM. Triage of cytology with HPV (or vice versa) improves specificity with a marginal decrease in sensitivity compared with cytology alone (Table 1) . Although HPV16/HPV18 genotyping is substantially more specific, its sensitivity is insufficient for a standalone test; and, based on limited data, it does not seem to add much sensitivity at the cost of specificity in combination with cytology (a currently recommended strategy for cervical cancer screening) ( Table 1) .
Several other biomarkers are currently being evaluated for the triage of HPV-positive women in cervical The analysis assumes a population size of 10,000, and prevalence estimates assume a 25% prevalence of AIN2/3. Estimates of sensitivity and specificity are derived from studies that were restricted to HIV-positive MSM, with the exception of E6/E7 mRNA. b Net sensitivity and specificity were calculated for sequential testing with cytology followed by HPV16/18 or E6/E7 mRNA.
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Cancer Cytopathology cancer screening that may better differentiate between transforming and benign HPV infections, including p16/ Ki-67 dual stain, host and viral DNA methylation, and HPV E6/E7 mRNA. 36, 87 For anal cancer screening, these biomarkers may have applications as primary screening tools, given the high background of HPV infections. Although some studies have evaluated p16/Ki-67 dual staining and DNA methylation in anal cancer screening, data are very limited, and we were not able to systematically evaluate the performance of methylation markers. The summary estimates for p16 or p16/Ki-67 dual stain are highly heterogeneous, which is related to differences in antibodies used, staining protocols, and interpretation. Our review indicates that E6/E7 mRNA exhibits promising performance, with greater specificity (albeit lower sensitivity) for detecting anal precancer compared with HPV DNA testing. However, it has been reported that the improved specificity of RNA testing versus DNA testing can largely be attributed to the limited number of HPV genotypes (HPV16, HPV18, HPV31, HPV33, and HPV45) included in 2 of the reported HPV E6/E7 mRNA tests. 92 This suggests that extended genotyping or type restriction of HPV assays could improve the clinical performance of HPV DNA testing for anal cancer screening, but more research with current assays is needed.
Risk-Based Management of Cervical and Anal Precancers
It is important to consider how various tests may be implemented for anal cancer screening. Again, cervical cancer screening can serve as a model and contrast. With HPV testing, cytology, and other available tests, we can now predict risk of cervical precancer and cancer with unprecedented precision. Recent screening and management guideline efforts have adapted a risk-based approach to screening, management, and treatment that focuses on using risk rather than assay-specific results to guide clinical management. 93, 94 The approach follows the principle of equal management of equal risks, meaning that, independent of how a certain risk level is arrived at, the management is the same. Screening, management, and treatment decisions are risk-based, and established clinical decision thresholds are used for the different management steps. The higher the risk of precancer, as a surrogate of cancer, the more likely treatment is going to be performed. The principle is illustrated in Figure 6A : The risk of cervical cancer in the general population is low, but it increases at each step when additional tests are performed that provide risk stratification. 36 We demonstrate an adaption of that model to anal cancer screening in HIVnegative MSM (Fig. 6B ) and HIV-positive MSM (Fig.  6C) . It is noteworthy that anal cancer screening is not population-based but focuses on certain high-risk groups. The disease prevalence in these populations is higher than the population prevalence of cervical precancer. Therefore, anal cancer screening starts at a higher risk level and it is more challenging to reassure patients of a low risk of precancer. HRA is the current standard for the surveillance of HIV-positive MSM, but there are no established management thresholds for anal cancer screening. 47 Another important difference is that a higher risk of precancer does not necessarily lead to more likely treatment decisions because of the morbidity associated with treating large anal precancers. 39 HPV DNA testing, which plays an increasingly important role in many cervical cancer screening programs worldwide, may be less important for anal cancer high-risk groups like HIV-positive MSM, because HPV status has limited influence on risk assessment. Although a negative test still may provide good reassurance, this will only benefit a small group of patients, because the HPV prevalence is so high. However, novel biomarkers, such as HPV mRNA, dual stain, HPV or host methylation, could have important roles for screening and management in HIV-negative and HIV-positive MSM.
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CONCLUSIONS
In considering the available evidence, it is clear that more research is needed to address several important knowledge gaps that would inform the implementation of anal cancer screening. Most of the literature on anal cancer natural history and screening has been focused on HIV-positive MSM, given the high burden of disease in this population. Future studies should aim to better understand anal cancer natural history in other high-risk populations to determine whether and how screening should be extended to these groups. The Study of the Prevention of Anal Cancer (SPANC) (an ongoing, prospective cohort study of HIV-positive and HIV-negative MSM based in Australia evaluating anal cytology, HPV genotyping, and other biomarkers for anal cancer screening) will help us to better understand the influence of HIV infection on the clinical performance of these different strategies. 95 The lack of
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Cancer Cytopathology studies evaluating anal cancer screening in HIV-positive women and those with previous HPV-associated, highgrade disease underscores the need for more research in these populations. 96 It is important to note that longitudinal studies evaluating the cumulative risk of anal precancer and cancer after testing with cytology, HPV, and/or other biomarkers are needed to establish optimal screening intervals. In cervical cancer screening, a negative cytology result does not have a strong, long-term negative predictive value because of its lower sensitivity, and screening must be repeated often. Conversely, HPV testing provides long-term reassurance against the future risk of precancer if the test is negative, allowing for extended intervals between screens. 38 For a population at high risk for anal cancer, such as HIVpositive MSM, a screening test should have high sensitivity to provide adequate reassurance that those who test negative will not develop anal precancer or cancer. 97 A better understanding of the risk of progression of HPV infection to anal precancer, and from anal precancer to cancer and the influence of HIV on these estimates would help to inform screening intervals, ages to start and stop screening, as well as decisions about treatment versus expectant management. 39 Defining clinical action thresholds for anal cancer screening and management will require more research regarding the possible benefits (eg, the prevention of cancer) versus potential harms (eg, complications related to screening and treatment), which may vary substantially between individual patients. The Anal Cancer/HSIL Outcomes Research (ANCHOR) study is an ongoing trial designed to evaluate the treatment of anal precancers versus watchful waiting and will address some of the major unresolved questions related to the progression of HSILs and clinical outcomes. 39 In summary, there are promising opportunities on the horizon that may improve the screening and surveillance of populations at high risk of anal cancer. Established assays and approaches from cervical cancer screening give us a head start, but we need to carefully evaluate them in the context of anal cancer natural history. Ultimately, important data gaps need to be filled so that we can evaluate the benefits and harms of anal cancer screening approaches in various populations.
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